provid
rational
develop
random
trial
abstract
purpos
influenza
viru
pandem
minor
patient
develop
rapidli
progress
pneumonia
lead
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
recent
metaanalysi
provid
support
prolong
corticosteroid
treatment
aliard
prospect
evalu
respons
oseltamivir
prolong
corticosteroid
treatment
patient
aliard
suspect
influenza
method
june
juli
patient
suspect
pneumonia
aliard
admit
intens
care
unit
icu
tertiari
care
hospit
influenza
confirm
realtim
revers
transcriptasepolymeras
chain
reaction
assay
eight
patient
oseltamivir
corticosteroid
treatment
initi
concomitantli
icu
admiss
sever
ard
receiv
methylprednisolon
mgkgday
other
receiv
hydrocortison
mgday
durat
day
result
patient
without
confirm
influenza
similar
diseas
sever
present
compar
respons
treatment
day
treatment
patient
experienc
signific
improv
lung
injuri
multipl
organ
dysfunct
score
p
twelv
patient
improv
lung
function
extub
discharg
aliv
icu
hospit
length
stay
mortal
day
respect
survivor
discharg
home
without
oxygen
supplement
conclus
ard
patient
without
confirm
influenza
prolong
lowtomoder
dose
corticosteroid
treatment
well
toler
associ
signific
improv
lung
injuri
multipl
organ
dysfunct
score
low
hospit
mortal
find
influenza
viru
pandem
minor
patient
develop
sever
pneumonia
lead
acut
respiratori
distress
syndrom
ard
multipl
organ
dysfunct
mod
associ
prolong
intens
care
unit
icu
stay
high
mortal
influenza
includ
experiment
clinic
studi
identifi
dysregul
system
inflamm
import
pathogenet
mechan
correl
diseas
sever
progress
signific
advanc
understand
cellular
mechan
corticosteroid
action
interact
corticosteroid
transcript
factor
inflammatori
cytokin
critic
ill
ard
within
new
pathogenet
construct
extens
rational
recent
provid
lowtomoder
dose
prolong
corticosteroid
treatment
adjunct
antivir
therapi
sever
case
influenza
event
grow
pandem
even
small
fraction
patient
develop
sever
pneumonia
respiratori
failur
overwhelm
countri
critic
care
hospit
infrastructur
recent
report
us
presid
council
advisor
scienc
technolog
present
plausibl
scenario
patient
requir
icu
admiss
unit
state
alon
follow
report
patient
initi
die
despit
best
support
treatment
includ
antivir
alon
corticosteroid
wide
use
sever
acut
respiratori
syndrom
sar
epidem
studi
indic
possibl
reduct
hospit
mortal
length
stay
implement
extrem
heterogen
treatment
regimen
vari
wide
time
initi
earli
vs
late
dosag
hydrocortison
equival
mgday
durat
day
treatment
made
assess
efficaci
unfeas
sinc
howev
three
random
trial
investig
prolong
lowtomoder
dose
corticosteroid
treatment
earli
acut
lung
injuri
ali
ard
find
recent
metaanalys
provid
stronger
foundat
guid
antiinflammatori
treatment
aliard
surprisingli
two
largest
studi
sever
influenza
aassoci
respiratori
failur
report
use
corticosteroid
patient
southern
hemispher
may
septemb
peak
season
influenza
juli
case
influenza
viru
confirm
argentina
death
respons
influenza
outbreak
take
account
recent
random
trial
develop
prospect
evalu
comprehens
protocol
manag
patient
suspect
influenza
viru
pneumonia
acut
hypoxem
respiratori
failur
admit
medic
icu
case
seri
describ
clinic
present
consecut
patient
respons
combin
highdos
oseltamivir
prolong
lowtomoder
dose
corticosteroid
treatment
patient
without
confirm
influenza
similar
diseas
sever
present
similar
respons
treatment
twelv
patient
improv
lung
function
extub
discharg
aliv
icu
hospit
mortal
hospit
municip
de
agudo
dr
lucero
tertiari
acut
care
hospit
blanca
bueno
air
argentina
patient
admit
medic
icu
influenzalik
ill
abnorm
chest
radiograph
sever
hypoxemia
requir
invas
mechan
ventil
manag
accord
preestablish
protocol
see
case
seri
determin
exempt
institut
review
board
approv
influenza
viru
infect
diagnos
test
nasopharyng
swab
specimen
realtim
revers
transcriptionpolymeras
chain
reaction
rrtpcr
accord
publish
guidelin
us
center
diseas
control
prevent
cdc
sever
ill
sever
mod
quantifi
measur
day
acut
physiolog
chronic
health
evalu
ii
sequenti
organ
failur
assess
sofa
score
latter
acut
organ
dysfunct
defin
acut
deterior
previous
normal
organ
sofa
score
greater
creactiv
protein
level
use
marker
system
inflamm
one
patient
met
diagnost
criteria
ard
accord
americaneuropean
consensu
definit
lung
injuri
score
li
quantifi
physiolog
respiratori
impair
ard
use
score
base
level
posit
endexpiratori
pressur
peep
ratio
pao
fraction
inspir
oxygen
fio
pao
fio
static
lung
complianc
c
st
degre
infiltr
present
chest
radiograph
ard
defin
sever
pao
fio
peep
c
cmh
patient
defin
improv
day
ard
achiev
lung
injuri
score
equal
lower
reduct
day
equal
greater
point
icu
admiss
result
microbiolog
analysi
nasopharyng
swab
respiratori
secret
blood
avail
patient
start
intraven
empir
antimicrobi
therapi
agreement
recent
guidelin
antivir
treatment
via
nasogastr
tube
highdos
oseltamivir
rational
provid
mg
twiceday
day
follow
mg
twiceday
day
dictat
clinic
evolut
corticosteroid
treatment
initi
icu
entri
concomitantli
antivir
treatment
similar
methodolog
recent
random
trial
patient
initi
start
hydrocortison
mg
intraven
everi
h
dosag
continu
icu
discharg
follow
lower
dose
hospit
discharg
mg
everi
h
day
mg
per
day
day
longer
durat
hydrocortison
treatment
comparison
prior
trial
dictat
recent
report
indic
shorter
durat
rapid
taper
treatment
associ
rebound
system
inflamm
clinic
deterior
similar
methodolog
anoth
recent
random
trial
patient
deterior
develop
sever
ard
pao
fio
b
peep
c
cmh
hydrocortison
chang
methylprednisolon
infus
initi
dose
mgkgday
day
follow
mgkgday
day
taper
day
corticosteroid
treatment
administr
chang
intraven
enter
oral
intak
restor
follow
extub
antiinflammatori
potenc
hydrocortison
mg
equival
methylprednisolon
mg
six
patient
sever
ard
bodi
weight
kg
initi
daili
methylprednisolon
dosag
mgday
patient
rang
aspect
care
manag
follow
preestablish
protocol
addit
antimicrobi
antivir
corticosteroid
treatment
follow
recent
guidelin
fluid
resuscit
sedat
analgesia
gastrointestin
thromboembol
prophylaxi
enter
nutrit
ventil
manag
incorpor
tidal
volum
peep
conform
ardsnet
recommend
standard
procedur
recruit
maneuv
prone
posit
ventil
refractori
hypoxemia
wean
mechan
ventil
prone
posit
ventil
institut
pao
fio
less
peep
equal
greater
cmh
patient
fail
improv
least
four
recruit
maneuv
h
patient
continu
kept
prone
posit
least
h
per
day
mechan
ventil
intub
patient
weekli
nonbronchoscop
bronchoalveolar
lavag
diagnost
threshold
bacteri
pneumonia
cfuml
statist
calcul
preform
use
sa
system
window
version
sa
institut
cari
nc
compar
clinic
characterist
admiss
time
patient
posit
neg
patient
without
sever
ard
standard
descript
statist
obtain
student
ttest
v
fisher
exact
test
wilcoxon
rank
sum
test
report
probabl
twosid
without
adjust
june
juli
patient
sever
hypoxemia
suspect
influenza
viru
pneumonia
admit
medic
icu
hospit
municip
de
agudo
dr
lucero
except
one
patient
transfer
anoth
medic
center
report
hospit
first
hospit
relat
diseas
patient
present
fever
myalgia
cough
progress
dyspnea
clinic
criteria
sever
sepsi
eight
patient
laboratoryconfirm
infect
one
patient
posit
rrtpcr
influenza
neg
four
patient
neg
influenza
exclud
falseneg
rrtpcr
result
recent
report
ten
percent
icu
patient
pneumonia
chest
radiograph
one
patient
one
quadrant
involv
show
bilater
infiltr
consist
sever
multilobar
pneumonia
ard
eight
patient
vasopressordepend
shock
tabl
provid
baselin
characterist
entir
group
n
patient
posit
n
neg
n
influenza
viru
rrtpcr
patient
n
without
sever
ard
n
patient
posit
neg
rtpcr
similar
diseas
sever
present
among
patient
two
chronic
obstruct
pulmonari
diseas
copd
one
year
old
prader
willi
syndrom
diabet
two
addit
patient
moder
obes
bmi
among
one
asthma
one
epilepsi
five
patient
cigarett
smoker
three
sever
ard
three
two
histori
alcohol
abus
two
sever
ard
two
icu
admiss
five
patient
leukocyt
per
cubic
millimet
six
patient
lymphopenia
less
leukocyt
per
cubic
millimet
seven
increas
creatin
kinas
level
one
iu
per
liter
six
elev
lactat
dehydrogenas
level
iu
per
liter
blood
cultur
obtain
eight
patient
without
growth
patient
pao
fio
receiv
peep
c
cmh
one
patient
one
quadrant
involv
chest
radiograph
lung
injuri
score
shown
tabl
patient
sever
ard
n
posit
septic
shock
higher
sofa
score
wors
ga
exchang
higher
peep
requir
one
requir
prone
ventil
four
patient
switch
methylprednisolon
within
h
icu
admiss
two
one
nonsurvivor
day
hydrocortison
treatment
seven
patient
either
sever
pneumonia
n
less
sever
ard
n
receiv
prolong
hydrocortison
treatment
none
requir
prone
ventil
ard
patient
improv
lung
injuri
score
day
tabl
show
find
day
treatment
base
statu
sever
lung
injuri
icu
entri
day
treatment
associ
signific
reduct
creactiv
protein
level
p
apach
ii
p
lung
injuri
p
sofa
p
score
day
reduct
sofa
score
observ
survivor
none
hospit
nonsurvivor
lung
injuri
score
improv
two
patient
one
nonsurvivor
figur
show
chang
pao
fio
lung
injuri
sofa
score
importantli
respons
patient
posit
neg
influenza
compar
degre
improv
methylprednisolon
sever
ard
hydrocortison
treatment
similar
patient
sever
ard
higher
rate
tracheotomi
vs
p
ventilatorassoci
pneumonia
vs
p
trend
toward
higher
lung
injuri
score
longer
durat
mechan
ventil
tabl
five
patient
extub
day
addit
six
day
four
patient
survivor
three
develop
ventilatorassoci
pneumonia
caus
klebsiella
pneumonia
acinetobact
baumani
proteu
mirabili
five
nondiabet
patient
requir
low
dose
insulin
glycem
control
gastrointestin
bleed
requir
transfus
neuromuscular
weak
observ
durat
corticosteroid
treatment
day
rang
one
patient
improv
lung
function
extub
discharg
aliv
icu
icu
nonsurvivor
male
smoker
histori
alcohol
abus
admit
septic
shock
sever
ard
neg
rtpcr
dysfunct
five
vital
organ
apach
ii
sofa
score
respect
fail
improv
lung
injuri
score
day
ard
die
icu
day
progress
mod
one
hospit
nonsurvivor
moder
obes
bmi
femal
copd
posit
rtpcr
without
shock
studi
entri
extub
day
mechan
ventil
die
icu
discharg
result
cardiac
arrest
electromechan
dissoci
preced
sudden
onset
sever
dyspnea
pulmonari
embol
suspect
autopsi
obtain
hospit
mortal
patient
without
shock
similar
vs
hospit
survivor
discharg
home
without
oxygen
supplement
aliv
day
physician
discret
outpati
taper
continu
sever
ard
day
four
without
sever
ard
day
first
case
seri
patient
suspect
influenza
viru
pneumonia
aliard
prospect
evalu
respons
combin
oseltamivir
prolong
lowtomoder
dose
corticosteroid
treatment
similar
prior
report
patient
young
year
old
otherwis
healthi
common
comorbid
chronic
lung
diseas
common
laboratori
find
includ
total
leukocyt
count
within
normal
limit
lymphopenia
increas
lactat
dehydrogenas
creatin
kinas
level
eight
patient
test
posit
influenza
viru
clinic
present
similar
neg
test
acut
hypoxem
respiratori
failur
develop
rapidli
median
day
frequent
associ
vasopressordepend
shock
one
patient
met
criteria
ard
singl
lung
involv
chest
radiograph
six
patient
sever
ard
condit
associ
icu
mortal
excess
day
treatment
patient
experienc
signific
reduct
creactiv
protein
level
pao
fio
lung
injuri
multipl
organ
dysfunct
score
fig
respons
patient
posit
neg
influenza
similar
compar
find
recent
earli
aliard
random
trial
treatment
well
toler
twelv
patient
improv
lung
function
extub
discharg
aliv
icu
mortal
similar
one
recent
report
canadian
critic
care
trial
group
collabor
lower
report
other
patient
popul
differ
lack
pregnant
morbidli
obes
patient
inclus
one
pediatr
patient
shorter
durat
symptom
present
two
largest
studi
report
corticosteroid
use
patient
subgroup
analys
respons
corticosteroid
treatment
provid
sever
influenza
share
common
pathogenet
mechanismdysregul
system
inflammationwith
lifethreaten
diseas
lead
aliard
mod
ard
patient
defici
corticosteroidmedi
downregul
inflammatori
cytokin
transcript
associ
diseas
progress
mortal
random
trial
prolong
lowtomoder
dose
corticosteroid
treatment
comparison
placebo
associ
signific
downregul
inflammatori
cytokin
transcript
reduct
pulmonari
system
inflamm
improv
pulmonari
multipl
organ
dysfunct
although
neuraminidas
inhibitor
effect
treat
influenza
viru
given
within
h
infect
patient
present
day
onset
symptom
time
present
affect
diseas
sever
antivir
agent
howev
directli
reduc
inflammatori
respons
lack
random
trial
patient
sever
influenza
valuabl
data
avail
recent
metaanalys
random
trial
patient
sever
sepsi
n
aliard
n
aliard
mani
sever
sepsi
studi
report
prolong
corticosteroid
treatment
associ
signific
reduct
marker
system
inflamm
consist
metaanalys
found
prolong
lowtomoder
dose
corticosteroid
treatment
associ
signific
physiolog
improv
acceler
resolut
shock
respiratori
failur
reduct
durat
icu
stay
day
increas
risk
nosocomi
infect
neuromuscular
weak
gastrointestin
bleed
importantli
sar
experi
seriou
side
patient
ard
n
improv
li
day
defin
lung
injuri
score
reduct
day
point
effectspsychosi
fatal
aspergillosi
avascular
necrosiswer
report
receiv
highdos
methylprednisolon
mgkgday
aliard
control
studi
n
investig
treatment
initi
within
day
diseas
onset
similar
protocol
show
signific
improv
surviv
overal
absolut
reduct
mortal
risk
ratio
confid
interv
metaanalysi
random
trial
sever
sepsi
report
risk
death
decreas
lowtomoder
dose
less
mg
hydrocortison
equival
longer
durat
treatment
metaanalys
found
surviv
advantag
lack
larg
confirmatori
trial
moder
degre
heterogen
across
studi
led
recent
consensu
statement
grade
evid
surviv
benefit
sever
sepsi
aliard
weak
grade
size
small
case
control
seri
major
limit
studi
random
trial
influenza
virusassoci
ard
need
evalu
effect
treatment
mortal
unlik
realiz
forese
futur
importantli
ard
patient
without
document
influenza
similar
respons
treatment
compar
recent
aliard
trial
patient
without
influenza
also
degre
improv
methylprednisolon
sever
diseas
higher
dose
hydrocortison
less
sever
diseas
lower
dose
treatment
similar
present
inform
natur
cours
sever
infect
still
limit
like
singl
icu
experi
replic
worldwid
base
observ
conclud
prolong
lowtomoder
dose
corticosteroid
treatment
safe
associ
signific
improv
lung
injuri
multipl
organ
dysfunct
score
report
small
reach
conclus
mortal
provid
rational
preliminari
data
design
random
trial
ard
lead
caus
death
patient
admit
hospit
influenza
viru
pneumonia
probabl
physicianssimilar
sar
recent
intern
respons
consid
adjunct
corticosteroid
therapi
simplifi
manag
take
consider
methodolog
earli
ard
trial
recommend
use
methylprednisolon
follow
initi
mg
intraven
bolu
methylprednisolon
administ
continu
infus
mgday
day
mgday
day
mgday
day
mgday
day
patient
later
develop
sever
ard
methylprednisolon
dosag
increas
mgkgday
day
patient
extub
patient
advanc
day
drug
therapi
taper
accord
schedul
follow
extub
infus
chang
intraven
bolus
given
everi
h
patient
toler
enter
intak
treatment
respons
monitor
daili
measur
lung
injuri
sofa
score
final
secondari
prevent
includ
infect
surveil
avoid
paralysi
import
minim
complic
associ
mask
prolong
glucocorticoid
treatment
